Investigational Drug Information for N,N-Dimethyltryptamine
✉ Email this page to a colleague
What is the development status for investigational drug N,N-Dimethyltryptamine?
N,N-Dimethyltryptamine is an investigational drug.
There have been 29 clinical trials for N,N-Dimethyltryptamine.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2007.
The most common disease conditions in clinical trials are Depression, Depressive Disorder, and Depressive Disorder, Major. The leading clinical trial sponsors are Johns Hopkins University, University Hospital, Basel, Switzerland, and Universidade Federal do Rio Grande do Norte.
Summary for N,N-Dimethyltryptamine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 509 |
| WIPO Patent Applications | 295 |
| Japanese Patent Applications | 43 |
| Clinical Trial Progress | Phase 2 (2007-04-01) |
| Vendors | 35 |
Recent Clinical Trials for N,N-Dimethyltryptamine
| Title | Sponsor | Phase |
|---|---|---|
| Safety and Tolerability of DMT in Healthy Adults | Universidade Federal do Rio Grande do Norte | Phase 1 |
| Phase 2 Clinical Trial of GH001 in Bipolar II Disorder | GH Research Ireland Limited | Phase 2 |
| A Trial of GH001 in Patients With Treatment-resistant Depression | GH Research Ireland Limited | Phase 2 |
Clinical Trial Summary for N,N-Dimethyltryptamine
Top disease conditions for N,N-Dimethyltryptamine
Top clinical trial sponsors for N,N-Dimethyltryptamine
US Patents for N,N-Dimethyltryptamine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
